|1.||Noninfiltrating Intraductal Carcinoma (DCIS)
|2.||Breast Neoplasms (Breast Cancer)
|1.||Kuerer, Henry M: 23 articles (12/2015 - 10/2003)|
|2.||Morrow, Monica: 19 articles (12/2015 - 02/2003)|
|3.||Hunt, Kelly K: 18 articles (12/2015 - 11/2002)|
|4.||Sasano, Hironobu: 14 articles (10/2015 - 03/2006)|
|5.||Kerlikowske, Karla: 14 articles (08/2015 - 11/2003)|
|6.||Mokbel, Kefah: 13 articles (08/2014 - 02/2003)|
|7.||Schnitt, Stuart J: 13 articles (01/2014 - 05/2005)|
|8.||Hwang, E Shelley: 13 articles (01/2012 - 01/2004)|
|9.||Rakovitch, Eileen: 12 articles (07/2015 - 09/2005)|
|10.||Bundred, N J: 12 articles (05/2015 - 08/2000)|
09/01/2004 - "The role of adjuvant tamoxifen in the treatment of DCIS was evaluated in two RCTs: one demonstrated a significant reduction in IBTR with tamoxifen and the other did not. "
01/01/2010 - "Tamoxifen seems helpful in treating DCIS."
01/01/2015 - "These include morphologic features variously defined, nomograms, algorithms and multi-gene expression assays-all of which have completed against the perceived conclusions of the randomized trials of irradiation and Tamoxifen for DCIS: "all subsets benefit". "
01/01/2014 - "A total of 158 patients with low- or intermediate-grade DCIS who underwent wide excision alone (without radiation or tamoxifen) were entered onto the trial from 1995 to 2002. "
01/01/2010 - "We review the results of the phase III trials of tamoxifen in DCIS as well as the emerging risk reduction therapies."
|2.||Estrogens (Estrogen)FDA Link
12/01/2011 - "The purpose of this study was to assess outcomes in a cohort of 14 well-informed women who elected non-surgical active surveillance with endocrine treatment alone for estrogen receptor-positive DCIS. "
01/01/2009 - "Patients (n = 23) diagnosed with ER-positive pure DCIS by stereotactic core biopsy were enrolled in a trial of neoadjuvant anti-estrogen therapy followed by definitive excision. "
09/01/2007 - "Materials and Methods : Histopathological evaluation and immunohistochemical study of anti-p63 and anti- CK8/18 was performed on selected archival cases of 7 ADH, 12 DCIS, 30 IDC of known clinicopathological data and previous estrogen receptor status (ER) for IDC. "
07/01/2015 - "In the primary prevention setting, excluding women diagnosed with DCIS, anti-estrogen use was 37%. "
07/01/2015 - "In multivariable analysis, women with a 5-year Gail risk ≥1.67% had approximately a 20% lower likelihood of anti-estrogen use compared to women with DCIS (p = 0.01). "
02/01/2013 - "The effects of hormone therapy on DCIS in clinical trial participants were assessed during the intervention, post-intervention, and entire followup periods, and in the observational study (OS; 30,421 CEE + MPA users and non-users and 18,657 CEE-alone users and non-users who met eligibility criteria similar to the clinical trial). "
09/01/2001 - "Recent studies have shown that ER-negative DCIS, unlike ER-positive DCIS, is hormone independent and does not respond to anti-oestrogen treatment. "
01/01/2014 - "Vav2 upregulation in DCIS relative to normal group was not associated with steroid hormone receptor and HER2 status, but was associated with the presence of concurrent invasion, including microinvasion (invasive foci of less than 1 mm). "
12/01/2013 - "A larger DCIS lesion (at least 15 mm), lack of hormone receptor expression, intermediate or high nuclear grade, diagnosis on core biopsy compared with vacuum-assisted biopsy, and non-cribriform subtype of DCIS were significantly associated with upstaging. "
10/01/2013 - "Histopathological features and hormone receptor/HER2 status were analysed in a first cohort of 65 cases of DCIS with a median follow-up of 112 months. "
|4.||anastrozole (Arimidex)FDA LinkGeneric
09/06/2003 - "Anastrozole for ductal carcinoma in situ."
01/01/2003 - "The potential role of anastrozole in the neoadjuvant setting, the management of DCIS, premenopausal breast cancer and breast cancer prevention is currently being investigated."
07/08/2014 - "The IBIS-II trial investigated breast cancer prevention with anastrazole in two cohorts: women with increased risk (Prevention), and women treated for ductal carcinoma in situ (DCIS). "
01/01/2003 - "A parallel trial will compare anastrozole against tamoxifen in 4,000 women with locally excised DCIS."
08/01/2007 - "In the ATAC study there were three DCIS lesions in the anastrozole arm and four in the tamoxifen arm in the women with ER positive invasive cancer. "
08/01/2007 - "The few clinical data that are available therefore suggest the aromatase inhibitors are likely to be effective in DCIS. "
05/01/2011 - "Despite the lack of clinical trials evidence, aromatase inhibitors are being prescribed for women with DCIS."
08/01/2007 - "This study has shown significant effects of aromatase inhibitors on DCIS indicating that these agents are therapeutically active in this condition."
02/28/2010 - "These findings could provide the scientific rationale as to employing aromatase inhibitors in the management of ER positive DCIS patients."
08/01/2007 - "Within the DCIS both aromatase inhibitors significantly reduced PgR expression and both drugs also produced a significant fall in proliferation. "
|6.||trastuzumab (Herceptin)FDA Link
01/01/2007 - "Intraductal trastuzumab treatment may be effective in the management of ductal carcinoma in situ of the breast with HER-2 overexpression."
01/01/2011 - "Further studies of trastuzumab for DCIS appear warranted. "
08/01/2007 - "Studies in the treatment of DCIS exploring partial breast radiation and trastuzumab are under way. "
01/01/2007 - "To test this hypothesis, a trial of neoadjuvant trastuzumab for DCIS has been opened at our institution. "
01/01/2013 - "Most HER2 FISH-ambiguous patients who received trastuzumab were HER2 IHC 3+, grade III, and had associated high-grade ductal carcinoma in situ. "
|7.||Progesterone Receptors (Progesterone Receptor)IBA
10/01/2011 - "Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast."
07/01/2014 - "Whole DCIS sections from 95 patients were evaluated by immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PgR), HER2, and Ki67. "
08/01/2011 - "We show that cytoplasmic HuR expression is elevated in both ADH and DCIS when compared to normal controls, and that this expression associated with high grade, progesterone receptor negativity and microinvasion and/or tumour-positive sentinel nodes of the DCIS. "
09/01/2008 - "Furthermore, NE-DCIS cases had significantly higher oestrogen and progesterone receptor and lower HER2 scores than non-NE-DCIS cases (P < 0.01). "
01/01/2007 - "As compared to sporadic tumours, BRCA1/2 tumours showed higher grade (P = 0.02), fewer ductal carcinoma in situ (P = 0.02), more frequent medullary histology (P = 0.02), more frequent negative oestrogen and progesterone receptors (P = 0.001 each). "
|8.||Proteins (Proteins, Gene)IBA
03/01/2008 - "The study suggests that saliva is a fluid suffused with solubilized by-products of oncogenic expression and that these proteins may be modulated secondary to DCIS. "
08/01/2001 - "An immunohistochemical study of these proteins was performed in 57 cases of DCIS and nine cases of morphologically apocrine DCIS. "
10/01/2013 - "Next, we performed immunohistochemical screening of nine stromal proteins in a second cohort of 82 DCIS cases, and correlated their expression with stromal architecture. "
04/01/2011 - "Prefractionated basic proteins were compared with total tissue lysates from human ductal carcinoma in situ tissue loaded on basic immobilized pH gradient strips prior to two-dimensional gel electrophoresis (2-DE). "
01/01/2010 - "Immunohistochemistry was used to examine the expression of a number of oxidative stress proteins, DNA repair proteins, and damage markers in 60 human mammary tissues which were classified as BH, DCIS or IBC. "
10/01/2015 - "Moreover, in ER-positive DCIS patients who received aromatase inhibitor (AI) before surgery, TS immunoreactivity was significantly decreased after AI treatment. "
07/08/2014 - "COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment."
07/01/2010 - "Positive correlation between aromatase and MMP-2 (p<0.001) and between MMP-9 and CD44 (p=0.030) were found in DCIS. "
07/01/2010 - "Aromatase was expressed in IDC and DCIS in 63 (57.3%) and 60 (67%) of the cases respectively; MMP-2 was similarly expressed in IDC and DCIS in 15 (13.60%) cases; MMP-9 was positively expressed in IDC and DCIS in 83 (75.50%) and 82 (74.50%) cases, respectively; CD44 was positively expressed in IDC and DCIS in 49 (44.50%) and 48 (42.60%) of the cases, respectively; all of them were highly correlated (p<0,001). "
11/01/2009 - "In the normal epithelium,aromatase was positive in 19(42.2%) and negative in 26 (57.8%) and a positive correlation, statistically significant was obtained when compared with IDC and DCIS(p<0.01). "
|10.||DNA (Deoxyribonucleic Acid)IBA
12/01/1997 - "Histopathologic features, including DNA studies, do not reliably predict the pathologic extent of DCIS, but mammographic size and focality do significantly correlate with pathologic size. "
10/01/1995 - "The median tumour size was 12 mm. The aim of the study was to support, with a larger sample, our recent findings with respect to DNA ploidy pattern in the selected group of ICs with predominance of DCIS (group I). "
01/01/2009 - "We have utilized a comprehensive and sensitive array-based DNA mapping technique, the methylated-CpG island recovery assay, to profile the DNA methylation pattern in ductal carcinoma in situ. "
01/01/2003 - "No significant differences, in neither morphology, immunohistochemistry, nor DNA ploidy, were shown between DCIS without and with invasion. "
01/01/2003 - "Small nuclear CIS, whether LCIS or DCIS, on the contrary, were DNA diploid with low proliferation, and no cases showed overexpression of c-erbB-2 and p53. "
|1.||Segmental Mastectomy (Lumpectomy)
08/01/2013 - "Those patients with pure DCIS treated with breast conserving surgery (BCS) benefited most with a relative risk reduction of nearly 50% for unnecessary SLNB. "
09/01/2001 - "The pattern of duct distribution was important: DCIS in which the involved ducts were more widely separated had a significantly greater recurrence of DCIS than when the involved ducts were more concentrated (p=0.08 for mammographically detected DCIS, p=0.07 for patients who underwent lumpectomy alone). "
12/01/2015 - "In patients treated with breast-conserving surgery for non-palpable DCIS, localization with iodine-125 seeds is superior to the WGL technique in reducing the risk of extensively involved resection margins."
06/01/2002 - "Lumpectomy followed by radiation is effective treatment for DCIS. "
12/01/2015 - "The aim of this study was to compare the efficacy of these localization techniques in the resection of DCIS by breast-conserving surgery. "
01/01/2004 - "There are indications from clinical studies that excision plus radiation therapy is as effective as mastectomy in reducing recurrence in patients with low-risk DCIS. "
03/01/2010 - "This study suggests that although oncoplastic reduction techniques are a reasonable approach for women with DCIS, stricter patient selection and improved confirmation of negative margins will minimize the need for either re-excisions or completion mastectomy and reconstruction."
01/19/2010 - "The agreement between pathological and radiological size of DCIS was poor in mastectomies but was improved by specimen slice radiography, suggesting specimen-handling techniques as a cause. "
04/01/2014 - "Given the ethical impossibility of conducting randomized controlled studies to compare NSM with conventional or skin-sparing mastectomy in DCIS, only long-term follow-up evaluations can demonstrate the safety of NSM. "
01/01/2012 - "From 1997 to 2007, we identified 969 patients with diagnoses of DCIS, among them 211 breasts in 207 patients were treated with mastectomy and comprise the study group. "
|3.||Drug Therapy (Chemotherapy)
08/01/2004 - "Since many issues are controversial such as the prognostic value of micrometastases and extramammary nodes as well as the use of SNB after primary chemotherapy and in ductal carcinoma in situ, further clinical studies are necessary."
10/01/2015 - "Other independent predictors of noninitiation included a diagnosis of ductal carcinoma in situ, declining radiation, and not receiving chemotherapy (stage I-III). "
01/28/2014 - "Chemotherapy without proper indications may not improve the prognosis of DCIS, pT(1mic) and pT(1a-b) patients. "
01/28/2014 - "And DCIS patients on chemotherapy had a much higher recurrence rate (P = 0.016) . "
04/01/2012 - "Patients with a pathologic complete response (pCR) or a ductal carcinoma in situ with microinvasion after chemotherapy were categorized into the pCR group. "
03/01/2013 - "Radiotherapy is effective in reducing the risk of local recurrence with about 50 % in all subgroups of patients with DCIS. "
01/01/2015 - "Studies were considered eligible if they investigated the efficacy of hypofractionated vs. standard radiotherapy or the efficacy of boost vs. no boost in patients with DCIS. "
03/01/2015 - "RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation."
09/01/2014 - "This study demonstrates HMGCR expression in DCIS and suggests HMGCR as a predictive marker of response to postoperative radiotherapy in DCIS, although the test for interaction was nonsignificant. "
02/01/2014 - "We report a population-based study of women with dcis treated with bcs and radiotherapy and an evaluation of the effect of age on local recurrence (lr). "
10/01/2006 - "Regardless of initial treatment, most patients with invasive local recurrence after treatment for DCIS can be treated and cured."
01/01/2016 - "Risk estimates (hazard ratios, odds ratios, and relative risks) and their 95% confidence intervals (CIs) were extracted to calculate the strength of the associations between predictive factors and the risk of LIR after treatment of DCIS. "
11/01/2014 - "Compared with patients not treated with radiation, those who received radiation for index DCIS were less likely to undergo repeat BCS (NCCN: 6.6 vs. 37 %, p = 0.001; CRN: 20 vs. 48 %, p = 0.0004) and more likely to experience surgical complications after treatment of recurrence (NCCN: 15 vs. 4 %, p = 0.17; CRN: 40 vs. 25 %, p = 0.09). "
08/01/2014 - "Cardiovascular morbidity and mortality after treatment for ductal carcinoma in situ of the breast."
11/01/2013 - "Regression of ductal carcinoma in situ after treatment with acupuncture."